{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:48:23Z","timestamp":1793947703860,"version":"4.8.0"},"reference-count":25,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T00:00:00Z","timestamp":1753574400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["NHMRC 2010\u20101012"],"award-info":[{"award-number":["NHMRC 2010\u20101012"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011369","name":"Royal Australian and New Zealand College of Ophthalmologists","doi-asserted-by":"publisher","award":["2007\u20102009"],"award-info":[{"award-number":["2007\u20102009"]}],"id":[{"id":"10.13039\/100011369","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Exper Ophthalmology"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We aimed to describe 1\u2010year outcomes of eyes switched to faricimab from first\u2010generation vascular endothelial growth factor (VEGF) inhibitors for neovascular age\u2010related macular degeneration (nAMD) in routine care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Multicentre, observational study of 383 eyes tracked in the Fight Retinal Blindness! registry switched to faricimab from aflibercept 2\u2009mg, ranibizumab, or bevacizumab between 1st January\u20141st August 2023 in Australia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      One\u2010year completion rates were high (335\/383 [88%]). The proportion of choroidal neovascular (CNV) lesions graded as inactive increased from 39% at switch to 63% at 12\u2009months (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). Mean visual acuity (95% Confidence Interval) decreased from 70.0 (68.6, 71.5) to 68.4 (66.7, 70.1) logarithm of the minimum angle of resolution letters (both approx. 6\/12). Mean treatment intervals increased from 7.2 to 10.5\u2009weeks (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). Eyes with active CNV at switch maintained mean VA \u22120.5 (\u22121.7, +0.7) letters; 50% were inactivated at 12\u2009months. Eyes with inactive CNV at switch lost \u22123.5 (\u22125.0, \u22121.9) letters; 15% had reactivation at 12\u2009months. Switchback occurred in 64\/383 eyes (17%), predominantly to aflibercept 2\u2009mg, that lost \u22121.9 letters without interval change at 12\u2009months. Adverse outcomes were in keeping with previous reports, with no cases of occlusive retinal vasculitis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We found that faricimab inactivated a significant proportion of CNV lesions that had been active using 1st generation VEGF inhibitors, with a significant extension of the treatment interval. A small reduction in VA occurred in switchers and eyes not switched through the same period.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ceo.14589","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T01:33:27Z","timestamp":1753666407000},"page":"1156-1167","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Outcomes After Switching to Faricimab in Neovascular Age\u2010Related Macular Degeneration: Data From the Fight Retinal Blindness! Registry"],"prefix":"10.1111","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6261-4679","authenticated-orcid":false,"given":"Adrian","family":"Hunt","sequence":"first","affiliation":[{"name":"The Save Sight Institute, Sydney Medical School The University of Sydney  Sydney New South Wales Australia"},{"name":"Department of Ophthalmology Westmead Hospital  Westmead New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"The Save Sight Institute, Sydney Medical School The University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Young","sequence":"additional","affiliation":[{"name":"Gladesville Eye Specialists  Gladesville New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Arnold","sequence":"additional","affiliation":[{"name":"Marsden Eye Specialists  Parramatta New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Game","sequence":"additional","affiliation":[{"name":"Port Macquarie Eye Centre  Port Macquarie New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Hooper","sequence":"additional","affiliation":[{"name":"The Save Sight Institute, Sydney Medical School The University of Sydney  Sydney New South Wales Australia"},{"name":"Visionary Eye Specialists  Hurstville New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Field","sequence":"additional","affiliation":[{"name":"Cairns Eye Surgery  Edge Hill Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Barry","sequence":"additional","affiliation":[{"name":"Blink Eye Clinic  Barton Australian Capital Territory Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Barthelmes","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology University Hospital and University of Zurich  Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gillies","sequence":"additional","affiliation":[{"name":"The Save Sight Institute, Sydney Medical School The University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,7,27]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201505889"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.02.014"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2024.01.004"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062655"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1102673"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.08.011"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2019.10.007"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S60893"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305327"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-023-02553-5"},{"issue":"7","key":"e_1_2_9_13_1","first-page":"4905","article-title":"Real\u2010World Treatment Patterns and Outcomes in the First 6 and 12 Months of Faricimab Use Among Eyes With Neovascular Age\u2010Related Macular Degeneration (nAMD) in the UK: FARWIDE\u2010nAMD","volume":"65","author":"Varma D.","year":"2024","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"8","key":"e_1_2_9_14_1","first-page":"2218","article-title":"FARETINA\u2010AMD\u2010 Early Treatment Patterns and Outcomes in Patients With Neovascular Age\u2010Related Macular Degeneration Initiating Faricimab: An IRIS RegistryTM Analysis","volume":"64","author":"Borkar D. S.","year":"2023","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e318296b271"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-023-02465-4"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2023.08.018"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-023-06222-x"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2016.4820"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.0530"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000003862"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/24741264241261441"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S424315"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2023.10.018"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2023.11.015"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-024-06421-0"}],"container-title":["Clinical &amp; Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ceo.14589","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T19:34:42Z","timestamp":1767036882000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ceo.14589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,27]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1111\/ceo.14589"],"URL":"https:\/\/doi.org\/10.1111\/ceo.14589","archive":["Portico"],"relation":{},"ISSN":["1442-6404","1442-9071"],"issn-type":[{"value":"1442-6404","type":"print"},{"value":"1442-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,27]]},"assertion":[{"value":"2025-03-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}